-
Olema Pharmaceuticals (OLMA) Announces New Clinical Trial Collaboration and Supply Agreement with Novartis in Frontline Metastatic Breast Cancer as well as $250 Million Equity Private Placement
-
Olema Oncology to Participate in Upcoming Investor Conferences
-
Citi Downgrades Arvinas Inc. (ARVN) to Neutral, 'we believe risk/reward appears balanced'
-
Citi Starts Olema Pharmaceuticals (OLMA) at Buy, 'Next-Gen Endocrine Therapy with Potential Across Multiple Lines of Breast Cancer'
-
Olema Oncology to Participate at Upcoming Investor Conferences

